Bayer today announced that its MEDRAD® Centargo multi-patient CT injector has secured 510(k) clearance from the U.S. Food and Drug Administration (FDA) to expand the use of compatible contrast agent ...

Bayer announced today 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its MEDRAD ® Centargo CT Injection System, an innovative multi-patient injector that drives workflow ...

LONDON--(BUSINESS WIRE)--Technavio has been monitoring the global contrast injectors market since 2015 and the market is poised to grow by USD 613.47 million during 2020-2024, progressing at a CAGR of ...

CHICAGO--(BUSINESS WIRE)--Bayer continues to advance its comprehensive Radiology portfolio with progress in the development pipeline as well as innovations around Artificial Intelligence (AI) and will ...

Centargo compatible with Ultravist® (iopromide), Isovue® (iopamidol), Optiray® (ioversol), Omnipaque™ (iohexol) and now, Visipaque™ (iodixanol) Follows recent FDA clearance to expand the use of ...

Follows recent FDA clearance to expand the use of compatible contrast agent presentations, adding single-dose vials in addition to Imaging Bulk Package presentations Radiology suites now have the ...